Vertex Taps Olympic Skier Lindsey Vonn to Boost Non-Opioid Pain Drug Awareness — Vertex Pharmaceuticals Incorporated

Event summary

Vertex partners with Olympic skier Lindsey Vonn to promote JOURNAVX®, a non-opioid pain medication approved in January 2025.
Vonn, recovering from injuries sustained during the 2026 Winter Games, endorses JOURNAVX® for managing moderate-to-severe acute pain.
JOURNAVX® has been prescribed to over one million Americans since its approval.
Vertex aims to raise awareness about non-opioid pain management options amid widespread opioid prescriptions.

The big picture

Vertex’s partnership with Lindsey Vonn underscores the growing demand for non-opioid pain management solutions, particularly in the wake of the opioid crisis. With over 80 million Americans prescribed acute pain medication annually, Vertex aims to position JOURNAVX® as a safer alternative. The collaboration highlights the strategic importance of celebrity endorsements in healthcare marketing, particularly for drugs targeting high-impact patient populations.

What we're watching

Market Adoption: How Vertex will leverage Vonn’s influence to drive JOURNAVX® prescriptions among acute pain patients.
Regulatory Dynamics: Whether the FDA’s approval of JOURNAVX® will accelerate broader acceptance of non-opioid pain treatments.
Competitive Positioning: The pace at which Vertex can differentiate JOURNAVX® in a market dominated by opioid-based pain management.